Accordingly, and in order to test the added value to explore the urinary sCD163 factor as “liquid kidney biopsy” biomarker in a large panel of serological and urinary LN/SLE biomarkers, 237 SLE patients were retrospectively selected. This evidence concerns the gene CD163 and lobular neoplasia.